Copyright

Creative Commons
You are free to share and adapt the content as per the creative commons license provided that SUMITT is acknowledged, under the following conditions:

**Attribution** - You must attribute the work to SUMITT but not in any way that suggests that SUMITT endorses you or your use of this work

**Non-commercial** - You may not use this work for commercial purposes.

**Share Alike** - If you alter, transform, or build upon this work, you may distribute the resulting work only under the same or similar license to this one.

See [http://creativecommons.org/licenses/by-nc-sa/3.0/](http://creativecommons.org/licenses/by-nc-sa/3.0/)

Disclaimer
Utilising the information in this document under a creative commons license does not negate the need to ensure other (if any) copyright requirements are met.
Acknowledgements

The author, Dr Enrico Cementon wishes to acknowledge the important contribution of several people to the production of these withdrawal guidelines.

I thank Mr Andrew Innes, who commenced writing these guidelines whilst he was a member of SUMITT, and Mr Leigh Cowley, Mr Shane Sweeney, Mr David Fryman and the whole SUMITT team for their guidance and support in the project. The NWMH Dual Diagnosis Implementation Committee and its chair, Ms Joy Barrowman, also provided considerable support.

I also thank Ms Pauline Kenny, Ms Amy Swan, Dr Lynda Berends, Ms Linda Jenner, Ms Barbara Hunter and Ms Janette Mugavin, authors of the 2009 Turning Point “Alcohol and Other Drug Withdrawal Practice Guidelines” for their permission to use selected tables for the purposes of producing these guidelines.

My final thanks go to Ms Laurence Hennessy of ProjectMinded for her helpful suggestions and thorough editing, formatting and design which enabled the production of this practical and comprehensive guideline.

Dr Enrico Cementon
SUMITT and DASWest
October 2011
Table Of Contents

i. Introduction ................................................................. 5

ii. How To Use This Manual .................................................. 7

1 Opioids ........................................................................ 9
   1.1 Assessment .......................................................... 9
   1.2 Planning Withdrawal ............................................. 10
   1.3 Management ....................................................... 11
   1.4 Post-Withdrawal Care .......................................... 15

2 Alcohol .......................................................................... 16
   2.1 Assessment .......................................................... 16
   2.2 Planning Withdrawal ............................................. 16
   2.3 Management ....................................................... 18
   2.4 Post-Withdrawal Care .......................................... 21

3 Amphetamines ................................................................ 22
   3.1 Assessment .......................................................... 22
   3.2 Planning Withdrawal ............................................. 23
   3.3 Management ....................................................... 24
   3.4 Post-Withdrawal Care .......................................... 26

4 Cannabis ......................................................................... 27
   4.1 Assessment .......................................................... 27
   4.2 Planning Withdrawal ............................................. 27
   4.3 Management ....................................................... 28
   4.4 Post-Withdrawal Care .......................................... 30

5 Benzodiazepines ............................................................. 31
   5.1 Assessment .......................................................... 31
   5.2 Planning Withdrawal ............................................. 32
   5.3 Management ....................................................... 34
   5.4 Post-Withdrawal Care .......................................... 35

6 Nicotine .......................................................................... 36
   6.1 Assessment .......................................................... 36
   6.2 Planning Withdrawal ............................................. 36
   6.3 Management ....................................................... 38
   6.4 Post-Withdrawal Care .......................................... 40

7 Clinical Support And Information Services ......................... 41

8 References ...................................................................... 45
   Appendix 1 Alcohol Withdrawal Scale ......................... 47
   Appendix 2 Fagerstrom Test for Nicotine Dependence ....... 49
One of the most common inquiries made to an addiction psychiatrist concerns the management of the drug dependent patient’s withdrawal syndrome. Substance withdrawal is defined as “the development of a substance-specific maladaptive behavioural change, with physiological and cognitive concomitants, that is due to the cessation of, or reduction in, heavy and prolonged substance use” (DSM-IV-TR). The signs and symptoms of withdrawal are usually the opposite of a substance’s direct pharmacological or intoxication effects.

Although the term “detoxification” implies the clearing of toxins, detoxification for the individual who has neurophysiologic substance dependence is the management of the withdrawal syndrome.

Indeed, the early recognition or prediction of an impending withdrawal syndrome is an important early clinical step, as a developing withdrawal syndrome may herald the onset of a potential psychiatric and medical emergency, which will require urgent intervention.

Acute drug withdrawal in psychiatric patients usually consists of the typical unpleasant physical, psychological and cognitive symptoms as in other drug-dependent people. However, drug withdrawal is also associated with onset of potentially serious medical conditions such as dehydration, electrolyte imbalance, cardiovascular instability, seizures, delirium and the exacerbation of associated or underlying psychiatric conditions. In rare situations, acute drug withdrawal may be life-threatening.

A main goal therefore, of managing drug withdrawal is the prevention of withdrawal complications. There are three immediate goals for a detoxification program:

1. To provide a safe withdrawal from the drug(s) of dependence and enable the patient to become drug-free
2. To provide a withdrawal that is humane and protects the patient’s dignity
3. To prepare the patient for ongoing treatment of his or her dependence on alcohol or other drugs.

(The American Society Addiction Medicine)

Important elements of humane withdrawal management include a caring staff, a supportive environment, sensitivity to cultural issues, confidentiality and the selection of appropriate medications.

However, the clinician must remember that drug dependence or addiction is frequently a long-term disorder and therefore detoxification is only the first step in a person’s recovery. One must also consider and plan for the person’s post-withdrawal support or a rehabilitation and recovery programme. The therapeutic relationship that forms between the person and staff during detoxification is an opportunity to explore alternatives to a substance-using lifestyle, to offer information and to motivate the person for longer-term treatment.

The two pharmacological strategies in withdrawal management are

1. Suppressing withdrawal through the use of cross-tolerant medication, usually with a longer acting drug that provides a milder, more controlled withdrawal
2. Reducing the withdrawal signs and symptoms through the alteration of another neuropharmacological process (Ries, Fiellin, Miller & Saitz 2009)
In the context of a mental health setting such as NWMH, it is typical that the person has gained entry into treatment due to the circumstances relating to the person’s psychotic, mood, anxiety or personality disorder and managing withdrawal is an associated clinical issue. Withdrawal may lead to further decompensation in the patient. A third important pharmacological strategy is therefore:

3. Continuing other psychotropic medications that were previously commenced for the person’s other psychiatric disorder(s).

Furthermore, there is much individual variation in signs, symptoms and duration of withdrawal. The detoxification care plan must be tailored to the person’s needs giving particular regard to associated psychiatric problems, if any. Anxiety symptoms and agitation in particular can cause an overestimation of the withdrawal severity even if using a withdrawal scale. The initial treatment plan may need to be adjusted as the withdrawal proceeds. If a patient’s decompensation is associated with inadequate withdrawal medication dosing, increasing the dosing is the appropriate response. If the withdrawal medication doses appear adequate, one may consider the addition of other non-addictive medication such as an antipsychotic, however you must first consider the potential for side effects and the interaction between the additional medication and the withdrawal medication. After the completion of detoxification, the patient’s need for these medications should be reassessed.

Special Needs

There are some patient groups that may require special consideration. The risks of withdrawal in pregnancy include miscarriage and premature labour and I recommend that you obtain specialist advice from one of the services listed in the Information section of these guidelines when planning to manage withdrawal in pregnant women or nursing mothers. Patients with medical comorbidities may require special monitoring and tailoring of medication regimens. Young people and adolescents’ physical drug dependence is often not as severe as that in adults and the response to detoxification may be more rapid. The involvement of the young person’s family in treatment should be considered.

These guidelines are partly the result of the need to revise the long-standing NWMH policies and procedures relating to the management of drug dependence in patients. I believe that the management of acute drug withdrawal is a core competency of all psychiatrists and my intention is that these guidelines will be a resource for NWMH psychiatrists, psychiatry trainees and other clinical staff who are endeavouring to achieve this competency.

Dr Enrico Cementon
SUMITT and DASWest
October 2011

Competing interests: None identified or declared
ii. How To Use This Manual

The following guidelines relate to Withdrawal Management Procedure NWMH 2.12.

It is the responsibility of all clinical staff to consider and implement the NorthWestern Mental Health (NWMH) acute inpatient and residential services withdrawal management procedure as stipulated in the guidelines.

Contact SUMITT (Substance Use Mental Illness Treatment Team) Ph.: 8387 2202 (during business hours) for information regarding the procedure and/or withdrawal management guidelines.

For further withdrawal management support and information consult:

1. Melbourne Health Addiction Medicine Resources intranet page
2. DACAS (Drug and Alcohol Clinical Advisory Service): ph: 9416 3611 or 1800 812 804 (all hours).

Principles of NWMH Alcohol and other Drug (AOD) withdrawal care

In the management and treatment of a consumer withdrawal from alcohol and/or other substance dependence, clinical staff working in NWMH acute inpatient and residential services need to adhere to the following key principles of care:

1. Harm and risk minimisation associated with medical complications arising from acute substance withdrawal is of paramount consideration when planning a withdrawal management program. Clinical staff need to consider the psychiatric medications prescribed concurrently for the treatment of the consumer’s psychiatric condition when planning a withdrawal management program.

2. The consumer has the right to be treated with dignity and respect throughout all stages of withdrawal management. This includes and is not limited to:
   a) Engaging the consumer in treatment options pre-and-post withdrawal treatment. Where this may prove difficult because language is a barrier, every effort must be made to accommodate the needs of the consumer.
   b) Minimising the discomfort associated with withdrawal
   c) Provision of pharmacotherapy treatment options pre-and-post treatment
   d) Provision of supportive care and counselling
   e) Provision of relevant information and resources

3. Evidence of long term benefits and reduced relapse rates for substance abuse are associated with post withdrawal treatment and care. Clinical staff are encouraged to discuss and document post withdrawal care options and link the consumer to appropriate services.

4. Exercising sound clinical judgement is reliant on best practice. It is expected that a comprehensive AOD assessment is undertaken as part of a mental health assessment and a withdrawal treatment plan that includes post withdrawal care for consumers with substance dependence who are at risk of a withdrawal syndrome be appropriately documented.
Withdrawal Management Guidelines

The Withdrawal Management Guidelines provide a comprehensive management approach to working with consumers withdrawing from alcohol and/or substance use within NWMH acute inpatient and/or residential services.

The following guidelines are listed by drug category according to the stages of the withdrawal management process.

Drug categories include:
1. Opioids
2. Alcohol
3. Amphetamines
4. Cannabis
5. Benzodiazepines
6. Nicotine

Stages of the withdrawal management process
1. Assessment - History, Examination and Investigation.
2. Planning withdrawal - Precautions and Withdrawal features.
3. Management - Supportive Care, Nutrition & Fluids, Medication, Monitoring and Ongoing Medication Plans.
4. Post-Withdrawal Care - Counselling Support Services, Self-Help Groups and Residential Rehabilitation Programs and other.

Documentation:
Clinical notes for each of the stages of the withdrawal management process are to be recorded in the following NWMH Forms:

<table>
<thead>
<tr>
<th>Stage Of Withdrawal Management Process</th>
<th>NWMH Policy Form/Template</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessment</td>
<td>1. ‘Alcohol and Other Drug Assessment’ section of the NWMH Mental Health Assessment Form (inpatient units and residential rehabilitation units)</td>
</tr>
<tr>
<td>Planning withdrawal</td>
<td>1. ‘Short Term Management Plan’ and ‘Alcohol and Other Drug Treatment Plan’ sections of the NWMH Mental Health Assessment Form 2. Inpatient Treatment Plan (inpatient units) 3. Recovery Action Plan (residential services)</td>
</tr>
</tbody>
</table>
1 Opioids

Heroin, Codeine, Morphine, Oxycodone, Methadone, Buprenorphine

1.1 Assessment

Reference Form:
1. NWMH Mental Health Assessment Form

History

Clinical staff are required to obtain a detailed history of consumers with a substance dependence and complete the ‘Alcohol & Other Drug Assessment’ section of the NWMH Mental Health Assessment form. This involves asking questions in relation to:

1. Drug use: quantity (amount, cost, number of injections per day), frequency, duration, route of administration, when last used, and features of dependence
2. Use of other drugs, (e.g. benzodiazepines, alcohol, etc.)
3. Withdrawal history: what has worked / not worked in the past
4. Home environment and social supports
5. Medical & Psychiatric history
6. Pregnancy

If clinical staff have a concern for the consumer’s drug-seeking behaviour, consult

1. Drugs & Poisons Regulation Group (DPRG) (Monday to Friday 9am-5pm) - 1300 364 545 or
2. Medicare Prescription Shopping Information Service - 1800 631 181

It is a legislative requirement for medical practitioners in Victoria to notify the Drugs and Poisons Regulation Group (DPRG) if there is reason to believe that a patient is drug-dependent and the patient seeks a drug of dependence or the medical practitioner intends to prescribe a drug of dependence to that patient.

The Medicare Prescription Shopping Information Service can provide further information on drug-seeking patients.

Examination

The treating doctor will examine the consumer for:

1. Vital signs (BP, pulse, respiratory rate)
2. Evidence of intoxication (pinpoint pupils, sedation, slurred speech, lowered BP, slowed pulse) or withdrawal from heroin or other drug use (see Table 1)
3. Evidence of complications of injecting drug use, including injection sites, liver, lymphadenopathy, cardiac, mental state.
### Table 1 - Withdrawl features

<table>
<thead>
<tr>
<th></th>
<th>insomnia</th>
<th>runny nose</th>
<th>poor appetite</th>
<th>anxiety</th>
<th>elevated blood pressure</th>
</tr>
</thead>
<tbody>
<tr>
<td>headaches</td>
<td>watery eyes</td>
<td>nausea</td>
<td>agitation</td>
<td>cravings</td>
<td></td>
</tr>
<tr>
<td>yawning</td>
<td>sweating</td>
<td>abdominal cramps</td>
<td>restlessness</td>
<td>strong desire to use</td>
<td></td>
</tr>
<tr>
<td></td>
<td>goosebumps</td>
<td>diarrhoea</td>
<td>tachycardia</td>
<td>muscle and joint pain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>hot and cold flushes</td>
<td>vomiting</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Investigation**

Treating doctor and/or clinical staff to further investigate for signs of drug dependence.

Consider:

1. Urinary drug screen - can be helpful in confirming the history
2. LFTs, HIV, Hep B&C testing at some stage with appropriate pre and post-test counselling (generally when withdrawal completed).

### 1.2 Planning Withdrawal

**Reference Forms:**

1. NWMH Mental Health Assessment Form - p.8 Short Term Management Plan & AOD treatment plan
2. Inpatient Unit - inpatient Treatment Plan
3. Residential Rehabilitation Unit - Recovery Action Plan

When planning a withdrawal treatment program, clinical staff must consider the following -

**Precautions**

1. Unstable medical /psychiatric condition
2. Unclear history of drug use
3. Pregnancy - consider referral for Methadone maintenance. Withdrawal during pregnancy can lead to miscarriage or premature delivery.
4. Polysubstance dependence (in this case you may need to discuss this with a specialist agency e.g. DACAS)
Withdrawal features - See Table 1
1. Although heroin withdrawal is unpleasant, it is not life threatening unless there is a serious underlying disease.
2. Withdrawal symptoms generally start within 6-24 hours of last use and last for 5-7 days with a peak at 48-72 hours. The main physical symptoms subside but sleep disturbance and mood changes can persist for weeks, and the desire to use again for much longer. Hallucinations and seizures are not typical features of heroin withdrawal and should alert you to other causes or disorders.

1.3 Management

Reference Forms:
1. Progress Notes
2. Medication Charts

Clinical staff will provide consumers with information, a clinical level of care and therapeutic support throughout the withdrawal management process. This includes:

Supportive care
Clinical staff to:
1. Provide supportive counselling including advising on coping strategies for cravings, maintaining motivation, sleep hygiene, relaxation techniques and exercising patience.
2. Provide print material about withdrawal from Opioids, e.g. ‘Getting through heroin withdrawal’ available from Turning Point.
3. Inform consumers of 24-hour telephone counselling available from DirectLine (1800 888 236)

Nutrition & Fluids
Encourage the consumer to:
1. Drink plenty of fluids (e.g. 2-3 litres of water or fruit juice daily)
2. Avoid caffeine and/or alcohol.
3. Eat light & healthy meals (small meals several times a day are better than one large meal)

Medication
The treating doctor is to engage the consumer, where possible, in discussion of the medical treatment options available and develop an integrated plan that is responsive to the AOD and mental health needs of the consumer.
Medical treatment options include:

Buprenorphine

1. **Buprenorphine is the most effective pharmacotherapy in the management of opioid withdrawal.**

2. Buprenorphine-assisted withdrawal requires much less adjunctive symptomatic medication.

3. Buprenorphine is a Schedule 8 medication. It can be prescribed by hospital-based doctors without a permit in Victoria, however, the doctor must notify the Drug and Poisons Unit (1300 364 545) of the intention to treat a drug-dependent person.

4. **Buprenorphine dosing is initiated after a client shows signs of opioid withdrawal. This is usually at least 6 hours after the last heroin dose or 24-48 hours after the last Methadone dose. If buprenorphine is prescribed too early it will precipitate opioid withdrawal symptoms.**

5. Over the first few days of buprenorphine dosing, daily review of patients should assess the need for dosing adjustments.

6. This period should also include information and reassurance.

7. Thorough information and support for clients should be available due to the high risk of overdose associated with lapse/relapse to opioid use after a period of abstinence.

Refer to Table 2 for buprenorphine dosing regimen.

**Table 2: Buprenorphine dosing regimen**

These doses are a guide only and the dose should be titrated according to the clinical response of the consumer.

<table>
<thead>
<tr>
<th>Day</th>
<th>Buprenorphine S/L tablet regime</th>
<th>Total daily dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>4mg at onset of withdrawal and additional 2 to 4 mg evening dose prn</td>
<td>4-8 mg</td>
</tr>
<tr>
<td>2</td>
<td>4mg mane, with additional 2 to 4mg evening dose prn</td>
<td>4-8 mg</td>
</tr>
<tr>
<td>3</td>
<td>4mg mane, with additional 2mg evening dose prn</td>
<td>4-6 mg</td>
</tr>
<tr>
<td>4</td>
<td>2mg mane prn; 2mg evening prn</td>
<td>0-4 mg</td>
</tr>
<tr>
<td>5</td>
<td>2mg prn</td>
<td>0-2 mg</td>
</tr>
<tr>
<td>6 &amp; 7</td>
<td>no dose</td>
<td></td>
</tr>
<tr>
<td>Total Proposed Dose</td>
<td></td>
<td>12-28 mg</td>
</tr>
</tbody>
</table>

*Source: Lintzeris et al (2006)*
Symptomatic management
The alternative to buprenorphine-assisted withdrawal is symptomatic management. Refer to Table 3

Table 3: Symptomatic management of opioid withdrawal symptoms
These doses are a guide only and the dose should be titrated according to the clinical response of the consumer.

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Medication</th>
<th>Dosing Regime</th>
<th>Notes</th>
</tr>
</thead>
</table>
| Anxiety, agitation, sweating, “goose flesh”                            | Clonidine          | Day 1: Test dose 50mcg
BP lying & standing at 30mins & 1 hour
Repeat: 100mcg at 4 hrs 150mcg at 8 hrs 200mcg at 12 hrs
Day 2: 200mcg QID
Day 3: 200mcg QID
Day 4: 150mcg QID
Day 5: 100mcg QID
Day 6: 50mcg QID | Cease dosing if: Systolic BP<80mmHg Pulse<50/min |
| Sleep disturbance, anxiety, agitation                                  | Diazepam           | Day 1: 5-10 mg each 4/24 at discretion of nursing staff
Day 2: 5-10 mg QID
Day 3: 5 mg QID/TDS
Day 4: 5mg TDS
Day 5: 5mg BD
Day 6: 5mg nocte | Max 40mg/day |
| Muscles & joint pains                                                  | Ibuprofen          | 400mg QID PRN                        | (provided no existing contraindications) |
| Nausea & Vomiting                                                      | Metoclopramide     | 10mg (Oral/ IMI) TDS PRN             |                                            |
|                                                                        | Prochlorperazine    | 5mg (Oral) TDS PRN                   |                                            |
|                                                                        | 12.5mg (IMI) BD PRN |                                    |                                            |
| Diarrhoea                                                              | Lomotil or Imodium | 1-2 tablets BD PRN                   |                                            |
| Abdominal cramps                                                       | Buscopan           | 10-20mg QID / PRN                    |                                            |
| Other                                                                  | Valerian (herbal alternative hypnotic) | 1-2 tablets nocte | Oral |
|                                                                        | Multivitamin       | 1 tablet Daily / BD | Dependent on nutritional status |
|                                                                        | including Bs & C   | 500mg 2 tablets 6/24 PRN            | dependent on hepatic status |

Source: DASWest procedure
Monitoring
Caution: The use of additional substances, such as opioids, alcohol and benzodiazepines, in combination with buprenorphine can cause respiratory depression, coma and death.

1. Close monitoring of the client is required where there is evidence or concern that a person may be using multiple substances, or is being administered other psychotropic medications, e.g. antipsychotics, antidepressants.
2. The level of monitoring depends on the severity of the clinical situation
   a) Intensive monitoring is mandatory if the patient is becoming sedated
   b) If the patient is fit and well, twice daily monitoring of vital signs, specifically pulse rate and respiratory rate, for 48 hours after the commencement of buprenorphine is sufficient.

Ongoing Medication Plan - Overdose Precaution
It is essential for clinical staff to warn consumers regarding the risk of overdose when:

1. Decreased tolerance after even a short period of abstinence can lead to death if the same quantities of opioids are used as before.
2. Mixing medications with alcohol or other drugs can also lead to overdose.

Longer-term maintenance substitution treatment (with buprenorphine or methadone) should be recommended to patients who:

1. Cannot stop, or markedly reduce, their heroin use during the withdrawal episode;
2. Relapse into regular heroin use as the dose of buprenorphine is reduced or ceased;
3. Do not feel confident about maintaining abstinence but do not want to relapse to dependent heroin use and the associated harms.

In consultation with the consumer, clinical staff are to explore post-withdrawal options prior to discharge. Inpatients wishing to commence buprenorphine maintenance treatment should continue buprenorphine until transfer to a community-based provider can be organised.

Community based prescribers and dispensers can be found through DirectLine 1800 888 236
1.4 Post - Withdrawal Care

Reference Forms:
1. Progress Notes
2. Inpatient Unit - Discharge Summaries
3. Residential Services - Recovery Action Plans

Clinical staff must be aware that inpatient withdrawal services can be a life-saving intervention for some clients. However, on its own, withdrawal treatment is not associated with long-term benefits. Ongoing participation in treatment is required to achieve long-term changes.

Clinical staff must encourage all consumers attempting withdrawal to pursue ongoing drug treatment. In consultation with the consumer plan for post-withdrawal care options. These options can include:

1. Counselling
2. Substitution maintenance treatment (with methadone or buprenorphine)
3. Self-help groups (e.g. Narcotics Anonymous)
4. Residential rehabilitation programs

Note: Consult with DirectLine (1800 888 236) regarding post-withdrawal treatment options and provide consumers with Directline contact details and information.

Other considerations:
1. Discuss safe-using, blood borne virus testing and vaccination.
2. Upon discharge, consult with the local AOD service (e.g. referral to methadone treatment, inpatient detox - DASWest 8345 6682 and Moreland Hall 93862876) in cases where the treatment plan is complex or where the intervention develops complications. Contact DACAS for clinical support and advice - 1800 812 804
2 Alcohol

Individuals drinking large amounts of alcohol regularly (e.g. daily) may experience withdrawal symptoms when ceasing or reducing their alcohol use. Withdrawal from alcohol should be a planned process.

2.1 Assessment

Reference Form:

1. NWMH Mental Health Assessment Form

History

Clinical staff are required to obtain a detailed history of consumers with a substance dependence and complete the “Alcohol & Other Drug Assessment” section of the NWMH Mental Health Assessment form. This involves asking questions in relation to:

1. Quantity, types of beverages, duration of use, time of last use, symptoms of dependence
2. Use of other drugs, e.g. benzodiazepines
3. Previous withdrawal attempts, any complications (e.g. seizures, delirium, psychosis)
4. Medical history and psychiatric history
5. Pregnancy.

Examination

The treating doctor will examine the consumer for:

1. Evidence of intoxication
2. Withdrawal signs (see Figure 1: Symptoms and duration of alcohol withdrawal)
3. Vital signs - BP, pulse rate, temperature, respiratory rate
4. Signs of liver disease, alcohol related brain injury, other complications of alcohol use.

Investigations

All staff to further investigate for signs of alcohol dependence.

1. Obtain Blood Alcohol Content Level (BAL) if breathalyser available
2. LFTs, FBE if indicated
3. Urine drug screen if concerned about undisclosed drug use.

2.2 Planning Withdrawal

Reference Forms:

1. NWMH Mental Health Assessment Form - p.8 Short Term Management Plan & AOD treatment plan
2. Inpatient Unit - inpatient Treatment Plan
3. Residential Rehabilitation Unit - Recovery Action Plan

When planning a withdrawal treatment program, clinical staff must consider the following:
Precautions
1. Serious complications (seizures, delirium or psychosis) in previous withdrawal attempts
2. Unstable medical or psychiatric problems (e.g. depression, insulin-dependent diabetes)
3. Unclear history of current drug and alcohol use
4. Pregnancy - 2nd trimester is probably the safest time to detoxify
5. Withdrawal from multiple drugs

Withdrawal Features

Figure 1: Symptoms and duration of alcohol withdrawal

Source: NSW Health (2008, p.22)

1. Withdrawal symptoms generally start within 6 to 24 hours of the last drink and peak over 36 to 72 hours.
2. They subside over a few days but mood and sleep disturbance may persist for weeks and the desire to drink for much longer.

Serious withdrawal complications include:
1. Severe hypertension
2. Seizures (usually occur within the first 48 hours following cessation of drinking)
3. Hallucinations, delirium
4. Arrhythmias
5. Precipitation/exacerbation of co-morbid medical or psychiatric disorders
2.3 Management

Reference Forms:
1. Progress Notes
2. Medication Charts
3. Alcohol Withdrawal Scale (AWS)

Clinical staff must provide consumers with information, a clinical level of care and therapeutic support throughout the withdrawal treatment process. This includes:

Supportive care
Clinical staff to:
1. Provide supportive counselling including advising on coping strategies, cravings, maintaining motivation, sleep hygiene, relaxation techniques and exercising patience
2. Provide print material about withdrawal from alcohol. E.g.: ‘Getting through Alcohol Withdrawal’ available from Turning Point
3. Inform the consumer of 24 hour telephone counselling available from DirectLine (1800 888 236).

Nutrition & Fluids
Clinical staff to encourage the consumer to:
1. Drink plenty of fluids (e.g. 2 - 3 litres of water or fruit juice daily)
2. Avoid caffeine and/or alcohol.
3. Eat light and healthy meals (small meals several times a day are better than one large meal)
4. Consider thiamine replacement (see dosing regimen - Table 4).

CAUTION: Suspected or diagnosed Wernicke’s encephalopathy is a serious condition requiring urgent intravenous thiamine in hospital.

Table 4: When and how to administer Thiamine

<table>
<thead>
<tr>
<th>Alcohol withdrawal presentation</th>
<th>Thiamine Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients</td>
<td>100-300 mg intravenously or intramuscularly for 3-5 days</td>
</tr>
<tr>
<td></td>
<td>300mg orally daily thereafter</td>
</tr>
<tr>
<td>Suspected Wernicke’s encephalopathy</td>
<td>At least 300 mg intravenously or intramuscularly for 3-5 days</td>
</tr>
<tr>
<td></td>
<td>100-300 mg orally daily thereafter</td>
</tr>
</tbody>
</table>

**Medication**

The treating doctor is to engage the consumer, where possible, in discussion of the medical treatment options available and develop an integrated plan that is responsive to the AOD and mental health needs of the consumer.

**Medical treatment options include:**

**Benzodiazepines**

Benzodiazepines effectively reduce withdrawal severity and the incidence of seizures and delirium. Oral diazepam is given according to the doses as described in Table 5.

**Table 5: Diazepam dose as a function of level of alcohol dependence and type of withdrawal setting**

<table>
<thead>
<tr>
<th>Level of dependence/setting of withdrawal</th>
<th>Example of diazepam dosing</th>
</tr>
</thead>
</table>
| Mild dependence in outpatient withdrawal setting | Day 1: 5-15mg qid  
Day 2: 5-10mg qid  
Day 3: 5-10mg tds  
Day 4: 10mg bd  
Day 5: 5mg bd |
| Moderate severity dependence in inpatient setting | 5-20mg 2 - 4 hourly as needed if CIWA Ar score > 10 for 3-4 days |
| High level of dependency and/or risk of complex withdrawal in inpatient setting | Loading doses of 10-20mg every 2-4 hours until light sedation achieved followed by CIWA Ar triggered or fixed dose therapy for 3-4 days |


Note: Doses of diazepam vary widely. Some consumers may only need 5-10 mg a day, others, particularly if they are tolerant to benzodiazepines because they have used them to treat unsuccessful withdrawals or anxiety, may need very high doses (160-200 mg) a day. Generally, doses greater than 40 mg a day require inpatient monitoring.

If diazepam is prescribed:

1. Adjust the dose according to the consumer’s response to medication
2. Withhold the medication if the client is continuing to drink alcohol or is intoxicated
3. Measure the blood alcohol level (BAL) if a breathalyser is available, although the BAL is not a good indicator to the commencement of sedation with diazepam. Sedation commences when clinically indicated, irrespective of the BAL, however caution is required when the BAL > 0.1 as there is a risk of interaction between alcohol and diazepam.
4. Benzodiazepines are drugs of dependence and their use should be short-term. Diazepam treatment is ceased once the withdrawal resolves, except when the treating doctor has assessed the patient to also be benzodiazepine-dependent. In this case, the minimum diazepam dose is continued in divided doses - refer to the Benzodiazepines section of this document.
Complex alcohol withdrawal:
1. Some clinicians recommend the use of short-acting benzodiazepines such as oxazepam and lorazepam for patients with severe liver disease, are elderly, or have delirium or dementia.
2. Haloperidol 0.5-2 mg oral/IM 2-4/24 PRN as an adjunct to benzodiazepines is recommended in severe alcohol withdrawal characterized by delirium (including delirium tremens), delusions and hallucinations.

Other
Symptomatic treatment may be indicated for:
1. Nausea and vomiting (metoclopramide/prochlorperazine),
2. Abdominal cramps (Buscopan),
3. Diarrhoea (Lomotil/Imodium)

Monitoring
Use the Alcohol Withdrawal Scale to assess the progress of withdrawal.

Ongoing Medication Plan
Alcohol pharmacotherapies are best used as part of a comprehensive management plan with appropriate psychosocial supports and may be commenced early in withdrawal treatment.

Alcohol anti-craving pharmacotherapies
1. Clinical staff, in consultation with the consumer, need to consider medications used to treat alcohol use disorders including the anti-craving therapies acamprosate (Campral®) and naltrexone (Revia®), and the aversive agent disulfiram (Antabuse®). These agents may be commenced in both inpatient and outpatient settings to prevent relapse in alcohol dependence.
2. Naltrexone is the preferred drug if there is no contraindication for its use. Choice of anti-craving medication is dependent upon drug interactions, patient experience, likely adherence to dosing, and potential adverse effects.
3. The PBS listing requires that naltrexone and acamprosate can only be subsidised by the PBS if the patient is aiming at total abstinence and is in a comprehensive management program,
4. Alcohol pharmacotherapies are best used as part of a comprehensive management plan with appropriate psychosocial supports, and naltrexone and acamprosate may be commenced early in withdrawal treatment.
5. In the event of relapse to alcohol use, it is recommended that the anti-craving therapies naltrexone and acamprosate be continued. Relapse would prompt review of the individual’s post withdrawal care plan
2.4 Post-Withdrawal Care

Reference Forms:
1. Progress Notes
2. Inpatient Unit - Discharge Summaries
3. Residential Services - Recovery Action Plans

Clinical staff must be aware that inpatient withdrawal services can be a life-saving intervention for some clients. However, on its own, withdrawal treatment is not associated with long-term benefits. Ongoing participation in treatment is required to achieve long-term changes.

Clinical staff must encourage all consumers attempting withdrawal to pursue ongoing drug treatment. In consultation with the consumer, plan for post withdrawal care options. These options can include:
1. Alcohol anti-craving pharmacotherapies
2. Counselling
3. Self-help groups (e.g. Alcoholics Anonymous)
4. Residential rehabilitation programs

Note: Consult with DirectLine (1800 888 236) regarding post-withdrawal treatment options and provide consumers with Directline contact details and information.
3 Amphetamines

Speed, go-ee, whiz, uppers, dexies, buzz, rev, crystal, meth, crystal meth, base, pure, ice, shabu ox blood and ice.

3.1 Assessment

Reference Form:

1. NWMH Mental Health Assessment Form

History

Clients with problematic amphetamine or other stimulant use may present with various symptoms: anxiety, agitation and restlessness; sleep disorders; drowsiness, lack of energy; mood disorders including depression or mood swings; or acute psychosis.

Clinical staff are required to obtain a detailed history of consumers with a substance dependence and complete the “Alcohol & Other Drug Assessment” section of the NWMH Mental Health Assessment form. This involves asking questions in relation to-

1. Drug use: which drugs, quantity, frequency, duration, when last used.
2. Route of drug use: sniffed, smoked, ingested or injected.
3. Use of other drugs: e.g. nicotine, alcohol, opioids, cannabis, benzodiazepines, etc.
4. Medical: Hypertension, arrhythmias, myocardial infarction, seizures and strokes
5. Psychiatric: Depression, psychotic symptoms. Is psychosis transient or persistent?

Examination

The treating doctor will examine the consumer for:

1. Vital signs (BP, pulse, respiratory rate)
2. Evidence of intoxication or withdrawal or other drug use.
3. Evidence of intravenous injection, including groin and neck. Evidence of nasal septum damage due to sniffing
5. Mental state examination.

Investigation

1. Clinical staff need to further investigate for signs of amphetamine dependence.
2. A urinary drug screen may be helpful in confirming the history and excluding other drug use. It may also be used to confirm the type of psychostimulant used.
3.2 Planning Withdrawal

Reference Forms:
1. NWMH Mental Health Assessment Form – p.8 Short Term Management Plan & AOD treatment plan
2. Inpatient Unit - inpatient Treatment Plan
3. Residential Rehabilitation Unit - Recovery Action Plan

Precautions
1. Unstable medical /psychiatric condition
2. Unclear history of drug use
3. Pregnancy - consider referral for Methadone maintenance. Withdrawal during pregnancy can lead to miscarriage or premature delivery.
4. Polysubstance dependence (in this case you may need to discuss this with a specialist agency e.g. DACAS)

Features of psychostimulant intoxication
Clinical staff need to be aware of the following features of psychostimulant intoxication and withdrawal and consider these when planning a withdrawal treatment program

Table 6: Features of psychostimulant intoxication

<table>
<thead>
<tr>
<th>Behavioural</th>
<th>Physiological</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confusion</td>
<td>Tremor</td>
</tr>
<tr>
<td>Aggression</td>
<td>Hypertension</td>
</tr>
<tr>
<td>Disinhibited behaviour</td>
<td>Tachycardia</td>
</tr>
<tr>
<td>Hyperactivity</td>
<td>Cardiac arrhythmias</td>
</tr>
<tr>
<td></td>
<td>Dilated Pupils</td>
</tr>
<tr>
<td></td>
<td>Stroke</td>
</tr>
</tbody>
</table>

Caution: Severe intoxication may lead to nausea and vomiting, dehydration and hyperthermia. This may lead (rarely) to cerebral oedema and death.
Withdrawal features
The first two- three days:
(‘The crash’) exhaustion, increased sleep needs and dysphoria are common. At this stage patients may suffer low levels of craving for the drug.
The following days/weeks
Clients often experience -
1. A degree of irritability, anxiety, severe cravings, mood swings and poor concentration.
2. Sleep is often disturbed, and appetite may increase markedly. Usually these symptoms begin to settle after a week or so, but sometimes mood swings and irritability may persist for longer.
3. Paranoid delusions and other psychotic phenomena, or lesser levels of persecutory ideation may be precipitated by heavy amphetamine use in susceptible people and these symptoms may worsen initially on withdrawal of the drug before resolving.
4. Depression may be precipitated or revealed by withdrawal.

3.3 Management

Reference Forms:
1. Progress Notes
2. Medication Charts

Clinical staff are to provide consumers with information, a clinical level of care and therapeutic support throughout the withdrawal treatment process. This includes:

Supportive care
Clinical staff to:
1. Provide supportive counselling including advising on coping strategies for cravings, maintaining motivation, sleep hygiene, relaxation techniques and exercising patience.

Nutrition & Fluids
Clinical staff need to be aware that craving for certain foods such as those rich in carbohydrates may occur and adequate provision of such foods and fluids will be necessary.
Clinical staff are to encourage the consumer to:
1. Drink plenty of fluids (e.g. 2 - 3 litres of water or fruit juice daily)
2. Avoid caffeine and/or alcohol.
3. Eat light and healthy meals (small meals several times a day are better than one large meal)
**Medication**

The treating doctor is to engage the consumer, where possible, in discussion of the medical treatment options available and develop an integrated plan that is responsive to the AOD and mental health needs of the consumer.

Medication may be of some use during the initial two to three days, but psychosocial support is the mainstay of treatment. There is no consistent evidence for the efficacy of any drug. If medical treatment is desired, the preferred approaches are:

**Benzodiazepines**

1. Benzodiazepines may be used in small doses for short periods for anxiety or sleep problems.
2. Encourage sleep hygiene, exercise and relaxation as alternatives or adjuncts to medication.
3. Longer acting benzodiazepines such as diazepam reduce anxiety and agitation over the course of the day, while shorter acting drugs such as temazepam are better where sleep problems predominate. Use one or the other.
4. **CAUTION:** Benzodiazepines are drugs of dependence and their use should be short-term

<table>
<thead>
<tr>
<th>Table 7: Benzodiazepine dose per day</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Generic Name</strong></td>
</tr>
<tr>
<td>-------------------</td>
</tr>
<tr>
<td>Diazepam (5 mg tablets)</td>
</tr>
<tr>
<td>Temazepam (10mg tablets)</td>
</tr>
</tbody>
</table>

*Source: DACAS Fact Sheet (2010)*

**CAUTION:**

1. Reduce the dose over 7 to 10 days.
2. Prescribe no more than 14 days’ continuous medication.

**Antidepressants**

Antidepressants treatment should be considered if significant depression persists.

**Amphetamine-induced psychosis**

1. The safe containment and management of disturbed behaviour and facilitation of restorative sleep are the goals of initial treatment.
2. Oral benzodiazepines, diazepam or lorazepam, are the first-choice medications.
3. Antipsychotic medications, e.g. olanzapine, are used when benzodiazepines are ineffective.

Amphetamine-induced psychosis is usually a transitory state that resolves with restorative sleep, medication and elimination of the drug and continuation of antipsychotic medication after 72 hours is usually unnecessary. (Guidelines for the medical management of patients with methamphetamine-induced psychosis, Drug & Alcohol Services South Australia 2006)
Monitoring
Close clinical observation is required.

Ongoing Medication Plan
Psychosocial support is the mainstay of ongoing treatment. There is no consistent evidence for the efficacy of any drug as maintenance treatment for stimulant dependence.

3.4 Post-Withdrawal Care

Reference Forms:
1. Progress Notes
2. Inpatient Unit - Discharge Summaries
3. Residential Services - Recovery Action Plans

Clinical staff must be aware that inpatient withdrawal services can be a life-saving intervention for some clients. However, on its own, withdrawal treatment is not associated with long-term benefits. Ongoing participation in treatment is required to achieve long-term changes.

Clinical staff must encourage all consumers attempting withdrawal to pursue ongoing drug treatment. In consultation with the consumer plan for post withdrawal care options. These options can include:
1. Counselling e.g. Turning Point’s ‘Methamphetamine Intervention’
2. Self-help groups
3. Residential rehabilitation programs

Note: Consult with DirectLine (1800 888 236) regarding post-withdrawal treatment options and provide consumers with Directline contact details and information.

Considerations:

Psychosocial treatment programmes
Cognitive-behaviour therapy has been demonstrated to be effective in preventing relapse in stimulant dependence. Clinical staff need to refer consumers to appropriate services.
4 Cannabis

Grass, pot, hash, weed, reefer, dope, herb, mull, buddha, ganja, joint, stick, buckets, cones, skunk, hydro, yarndi, smoke and hooch

4.1 Assessment

Reference Form:
1. NWMH Mental Health Assessment Form

History
Clinical staff are required to obtain a detailed history of consumers with a substance dependence and complete the ‘Alcohol & Other Drug Assessment’ section of the NWMH Mental Health Assessment form. This involves asking questions in relation to:

1. Drug use: quantity, frequency, duration, how used (joints, bongs, pipes, oral), when last used
2. Use of other drugs (e.g. nicotine, benzodiazepines, alcohol, opioids)
3. Withdrawal history: what has worked / not worked in the past
4. Home environment and social supports
5. Medical & psychiatric history

Examination
The treating doctor will examine the consumer for:

1. Vital signs (BP, pulse, respiratory rate).
2. Evidence of intoxication (reddened sclera, sedation or drowsiness) or withdrawal from cannabis (see withdrawal features listed below); or other drug use.
3. Evidence of complications of cannabis use, including respiratory and neuropsychiatric problems.

Investigation
1. Clinical staff to further investigate for signs of cannabis dependence.
2. Urinary drug screen may be helpful in confirming the history and excluding other drug use.

4.2 Planning Withdrawal

Reference Forms:
1. NWMH Mental Health Assessment Form - p.8 Short Term Management Plan & AOD treatment plan
2. Inpatient Unit - inpatient Treatment Plan
3. Residential Rehabilitation Unit - Recovery Action Plan
When planning a withdrawal treatment program, clinical staff need to consider the following:

**Precautions**
Pregnancy - 2nd trimester is probably the safest time to detoxify

**Withdrawal features**
1. Not all regular cannabis users will experience significant withdrawal from cannabis, and in many cases withdrawal will be mild and of short duration.

2. Common features of withdrawal include: anxiety, agitation, restlessness, irritability, nausea, dysphoria, lethargy, cravings, sleep disturbances (including vivid dreams, nightmares, and insomnia), sweating, and headaches.

3. Although cannabis withdrawal is unpleasant, it is not life threatening.

4. Withdrawal symptoms generally start within 1 - 2 days of last use and most symptoms subside within 4 to 7 days.

5. Some features such as sleep disturbances and cravings may persist for weeks.

6. Hallucinations and seizures are not typical features of cannabis withdrawal and should alert you to other causes or disorders.

**4.3 Management**

**Reference Forms:**
1. Progress Notes
2. Medication Charts

Clinical staff must provide consumers with information, a clinical level of care and therapeutic support throughout the withdrawal treatment process.

The key principles in managing cannabis withdrawal are support and monitoring.

**Medication has a limited role.**

**Supportive care**
Clinical staff must:

1. Provide verbal and written information regarding likely cannabis withdrawal features and coping strategies

2. Provide supportive counselling including coping strategies for cravings, sleep hygiene and relaxation techniques, and strategies for maintaining motivation and exercising patience

3. Inform consumers of 24-hour telephone counselling/ crisis management available from DirectLine (1800 888 236)

**Nutrition & Fluids**
Encourage the consumer to:

1. Drink plenty of fluids (e.g. 2-3 litres of water or fruit juice daily)
2. Avoid caffeine & alcohol
3. Eat light & healthy meals (small meals several times a day are better than one large meal).
Medication

1. The treating doctor is to engage the consumer, where possible, in discussion of the medical treatment options available and develop an integrated plan that is responsive to the AOD and mental health needs of the consumer.

2. Most individuals withdrawing from cannabis do not require medication. Medications described in Table 8 should only be considered for consumers expressing concern regarding their ability to cope with symptoms (consumer expectancy), or for those consumers experiencing particular difficulties during withdrawal.

Note: It is often advantageous to address the client’s use of tobacco during attempts at ceasing cannabis. Nicotine withdrawal may occur and should be managed.

Table 8: Medications for the symptomatic management of cannabis withdrawal

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Medications</th>
<th>Dose</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sleep disturbance</td>
<td>Temazepam</td>
<td>10-20mg nocte</td>
<td>Up to 7 days</td>
</tr>
<tr>
<td>Anxiety, agitation &amp; irritability</td>
<td>Diazepam</td>
<td>5-10mg divided doses up to 20mg daily</td>
<td>Reducing over 3-7 days</td>
</tr>
<tr>
<td>Abdominal cramps</td>
<td>Buscopan</td>
<td>10-20mg</td>
<td>QID/ PRN</td>
</tr>
<tr>
<td>Headaches &amp; other pain</td>
<td>Paracetamol, Ibuprofen</td>
<td>500mg 2 tablets, 200mg 2 tablets</td>
<td>6/24/ PRN, QID/ PRN</td>
</tr>
<tr>
<td>Nausea &amp; vomiting</td>
<td>Metoclopramide, Prochlorperazine</td>
<td>10mg (Oral/ IMI), 5mg (Oral), 12.5mg (IMI)</td>
<td>TDS/ PRN, TDS/ PRN, BD/ PRN</td>
</tr>
</tbody>
</table>


Monitoring

Close clinical observation is required.

Ongoing medication plan

Psychosocial support is the mainstay of ongoing treatment. There is no consistent evidence for the efficacy of any drug as maintenance treatment for cannabis dependence.
4.4 Post-Withdrawal Care

Reference Forms:
1. Progress Notes
2. Inpatient Unit - Discharge Summaries
3. Residential Services - Recovery Action Plans

Clinical staff must be aware that inpatient withdrawal services can be a life-saving intervention for some clients. However, on its own, withdrawal treatment is not associated with long-term benefits. Ongoing participation in treatment is required to achieve long-term changes.

Clinical staff must encourage all consumers attempting withdrawal to pursue ongoing drug treatment. In consultation with the consumer, plan for post withdrawal care options. These options can include:

1. Consultation with Cannabis Information and Helpline 1800 30 40 50
2. Counselling
3. Self-help groups
4. Residential rehabilitation programs

Note: Consult with DirectLine (1800 888 236) regarding post-withdrawal treatment options and provide consumers with Directline contact details and information.
5 Benzodiazepines

Alprazolam, bromazepam, clonazepam, diazepam, flunitrazepam, lorazepam, nitrazepam, oxazepam, temazepam

Benzodiazepine users may present in a variety of ways: requesting a script for a specific benzodiazepine, stating they need benzodiazepines to assist in heroin or alcohol withdrawal, or to treat an anxiety disorder or sleep problems.

There are various patterns of benzodiazepine use and dependence. Clients taking one tablet a day for years require a different approach from the heavy user. There are some cases where benzodiazepine prescribing is appropriate to treat a severe anxiety disorder. Each client needs a careful assessment including an evaluation of the reasons for and against continued use prior to embarking on the management guidelines outlined below.

People using high doses of benzodiazepines regularly (e.g. daily) over an extended period of time may experience a withdrawal syndrome when ceasing or reducing their benzodiazepines use. Because of the risk of withdrawal syndrome, benzodiazepine withdrawal requires careful planning.

5.1 Assessment

Reference Form:
1. NWMH Mental Health Assessment Form

History
Clinical staff are required to obtain a detailed history of consumers with a substance dependence and complete the ‘Alcohol & Other Drug Assessment’ section of the NWMH Mental Health Assessment form. This involves asking questions in relation to:

1. Drug use: quantity, frequency, duration, when last used
2. Assess which doctors prescribed how much of which benzodiazepine
3. Use of other drugs: (e.g. nicotine, alcohol, opioids, cannabis)
4. Withdrawal history, especially a history of complications – seizures, delirium
5. Medical & psychiatric history
6. Home environment and social supports
7. Sleep history, especially if they are using benzodiazepines for sleep

Examination
The treating doctor will examine the consumer for:

1. Vital signs (BP, pulse, respiratory rate)
2. Evidence of intoxication (drowsiness, sedation, nystagmus) or withdrawal; other drug use
3. Evidence of intravenous injection including groin and neck.
Investigation
Clinical staff to further investigate for signs of substance use. Urinary drug screen may be helpful in confirming the history and excluding other drug use.

Collateral information
1. For a heavy benzodiazepines user it is desirable for clinical staff to contact the Medicare Australia’s Prescription Shopping Program (1800 631 181) to find out if the client has been identified under the program and receive information on the amount and type of PBS medication supplied to that client.
2. It is a legislative requirement for medical practitioners in Victoria to notify the Drugs and Poisons Regulation Group (DPRG) if there is reason to believe that a patient is drug-dependent and the patient seeks a drug of dependence or the medical practitioner intends to prescribe a drug of dependence to that patient.

5.2 Planning Withdrawal

Reference Forms:
1. NWMH Mental Health Assessment Form - p.8 Short Term Management Plan & AOD treatment plan
2. Inpatient Unit - Inpatient Treatment Plan
3. Residential Rehabilitation Unit - Recovery Action Plan

Precautions
1. Elderly and people with chronic physical illness are at greater risk of benzodiazepine withdrawal toxicity due to reduced metabolism and physical frailty. Withdrawal must be closely monitored.
2. Pregnancy requires gradual, supervised reduction of benzodiazepines rather than abrupt withdrawal.

Withdrawal features
The onset and duration of withdrawal symptoms depend on the duration of action of the benzodiazepine.

Short Acting Benzodiazepines e.g. alprazolam, temazepam, oxazepam
Withdrawal of short-acting benzodiazepines generally starts within 1-2 days of last use, peak at 7-14 days and gradually subsides.

Long-acting benzodiazepines e.g. diazepam, clonazepam, flunitrazepam
Withdrawal of long acting benzodiazepines generally have a less severe withdrawal starting at 2-7 days, peaking around 20 days, and abate after a few weeks and, less commonly, months.

It can be difficult to differentiate between some symptoms of benzodiazepine withdrawal such as anxiety, agitation, insomnia and mood changes and those symptoms of an underlying or associated mood and/or anxiety disorder. If the presence of an independent mood or anxiety disorder is probable, it must be concurrently treated.

Benzodiazepine withdrawal is often protracted. The first phase of withdrawal can occur in the inpatient setting, especially when there has been a high level intake for a prolonged period, and the remaining withdrawal, which is usually more prolonged, is managed in the community.
Common features of benzodiazepine withdrawal

- Irritability, anxiety, restlessness, insomnia
- Panic attacks
- Muscle aches, cravings, headaches
- Numbness, tingling, paraesthesias
- Hypersensitivity to noise, light and touch
- Dizziness
- Impaired concentration and memory
- Depersonalization and derealisation, other perceptual disturbances
- Psychosis (less commonly)

Note: Withdrawal seizures are more likely to occur after abrupt cessation of long-term use of high doses.

Table 9: Benzodiazepine equivalent doses & conversion table

<table>
<thead>
<tr>
<th>Benzodiazepine</th>
<th>Trade Name</th>
<th>Elimination Rate (Hours)</th>
<th>Equivalent Diazepam Dose 5mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALPRAZOLAM</td>
<td>Xanax, Kalma</td>
<td>Med (6 - 20)</td>
<td>0.5 - 1.0 mg</td>
</tr>
<tr>
<td>BROMAZEPAM</td>
<td>Lexotan</td>
<td>Med</td>
<td>3 - 6 mg</td>
</tr>
<tr>
<td>CLONAZEPAM</td>
<td>Rivotril</td>
<td>Long</td>
<td>0.5 - 1.0 mg</td>
</tr>
<tr>
<td>DIAZEPAM</td>
<td>Valium</td>
<td>Long (30 - 60)</td>
<td>5 mg</td>
</tr>
<tr>
<td>FLUNITRAZEPAM</td>
<td>Rohypnol</td>
<td>Med (10 - 25)</td>
<td>1 - 2 mg</td>
</tr>
<tr>
<td>LORAZEPAM</td>
<td>Ativan</td>
<td>Med (10 - 20)</td>
<td>0.5 - 1.0 mg</td>
</tr>
<tr>
<td>NITRAZEPAM</td>
<td>Mogadon, Alodorm</td>
<td>Med (20 - 60)</td>
<td>5 - 10 mg</td>
</tr>
<tr>
<td>OXAZEPAM</td>
<td>Serepax, Murelax, Alepam</td>
<td>Short - medium (5 -10)</td>
<td>15 - 30 mg</td>
</tr>
<tr>
<td>TEMAZEPAM</td>
<td>Normison, Euhypnos, Temaze, Temtabs, Nocturne</td>
<td>Short (10 - 17)</td>
<td>10 - 20 mg</td>
</tr>
</tbody>
</table>

Source: (Adapted from SAW Manual – New concepts in drug withdrawal 1995 p.71)

Note: Alprazolam may present specific treatment challenges. Transfer to a long-acting benzodiazepine such as diazepam may require either prescribing more than the estimated equivalent diazepam dose in divided dosages, or “cross-tapering” alprazolam to diazepam, or both.
5.3 Management

Reference Forms:
1. Progress Notes
2. Medication Charts

The treating doctor is to engage the consumer, where possible, in discussion of the medical treatment options available and develop an integrated plan that is responsive to the AOD and mental health needs of the consumer.

Supportive Care
Clinical staff to provide:
1. Frequent regular supervision to ensure the client is reducing comfortably and dealing with lifestyle and psychological issues
2. Supportive counselling including advice on coping strategies for cravings, maintaining motivation, sleep hygiene, relaxation techniques and exercising patience.
3. Verbal and written information regarding likely withdrawal features and coping strategies. Reconnexion can provide helpful written resources.

Nutrition & Fluids
Encourage the consumer to:
1. Drink plenty of fluids (e.g. 2-3 litres of water or fruit juice daily)
2. Avoid caffeine and/or alcohol
3. Eat light and healthy meals (small meals several times a day are better than one large meal).

Medication
The recommended approach to managing benzodiazepine withdrawal comfortably is:
1. Switch to a single, long-acting benzodiazepine, usually diazepam (see Table 9).
   a) Dose equivalents may be unreliable, but even a client who is assessed to be taking > 40 - 60 mg diazepam or equivalent per day will not usually need more than 60 - 80 mg diazepam per day, however this should be administered in divided doses and in an inpatient or residential setting.
   b) The aim of treatment is to prevent withdrawal, not to cause intoxication.
   c) Light sedation is a marker of tolerance and can be taken as the endpoint in determining the initial total daily dose.
   d) A high total daily dose such as 60 - 80 mg can be reduced more rapidly in the inpatient or residential setting e.g. taper down to 30 mg daily in one week.
2. After discharge from the inpatient unit (and for consumers who are being managed solely as outpatients) the total daily dose of diazepam should not exceed 30 mg in order to minimise the risks of interactions with other substances.
3. In the community setting, there should be a single prescriber and a single dispensing pharmacy. Controlled dispensing from the pharmacy should be considered e.g. daily, twice-weekly or weekly.
4. Clear and effective liaison with other community prescribers, e.g. GPs, to facilitate continuity of care and to prevent or minimise “doctor-shopping”.

5. Reduce the dose of benzodiazepines at a rate of 10 per cent every one-to-four weeks. The rate of reduction varies greatly and should be negotiated with the consumer.

**Monitoring**

1. The onset of excessive sedation, ataxia, poor motor coordination or other signs of benzodiazepine toxicity should alert clinical staff that the benzodiazepine dose is too high or there is concurrent administration of other sedating medications or substances.

2. The close monitoring of the consumer will depend on the clinical situation and may require monitoring of vital signs and conscious state.

**Ongoing medication plan**

1. The tapering of the benzodiazepine dose should be gradual and will usually occur in the community setting. The rate of dose reduction is about 10 per cent every one–to–four weeks and depends on the individual consumer’s withdrawal symptoms, reasons for prescription, lifestyle, personality, environmental stressors and available supports.

2. Adjuvant pharmacotherapies such as antidepressants and mood stabilisers may be required for associated or underlying anxiety or depressive or other mood disorders.

**5.4 Post-Withdrawal Care**

**Reference Forms:**

1. Progress Notes
2. Inpatient Uni - Discharge Summaries
3. Residential Services - Recovery Action Plans

Clinical staff must be aware that inpatient withdrawal services can be a life-saving intervention for some clients. However, on its own, withdrawal treatment is not associated with long-term benefits. Ongoing participation in treatment is required to achieve long-term changes.

Clinical staff must encourage all consumers attempting withdrawal to pursue ongoing drug treatment. In consultation with the consumer, plan for post withdrawal care options. These options can include:

1. Supportive Counselling - from a GP or other health worker (e.g. home based withdrawal worker from the local AOD agency
2. Contact Reconnexion 1300 273 266 - telephone support and information and counselling service
3. Provision of coping strategies for cravings, maintaining motivation, sleep hygiene, relaxation techniques and exercising patience
4. Residential rehabilitation programs.

Note: Consult with DirectLine (1800 888 236) regarding post-withdrawal treatment options and provide consumers with Directline contact details and information.
6 Nicotine

Nicotine dependence may be addressed in conjunction with treatment for another drug or other mental health issues in both residential and outpatient settings. Most inpatient and community care units have implemented non-smoking policies and the following withdrawal guidelines will be used in the context of those policies.

6.1 Assessment

Reference Form:
1. NWMH Mental Health Assessment Form

History
Clinical staff are required to obtain a detailed history of consumers with a substance dependence and complete the ‘Alcohol & Other Drug Assessment’ section of the NWMH Mental Health Assessment form. This involves asking questions in relation to:
1. Quantity, types of tobacco products, duration of use, time of last use
2. Use of other drugs
3. Previous withdrawal attempts, any complications, periods of sustained abstinence
4. Medical history and psychiatric history
5. Pregnancy.

Examination
The treating doctor will assess the consumer for the physical consequences of smoking.

Investigations
The investigations performed will depend on findings on examination of the consumer. Some smoking policies require that the Fagerstrom Test for Nicotine Dependence be used to assess the level of nicotine dependence.

6.2 Planning Withdrawal

Reference Forms:
1. NWMH Mental Health Assessment Form - p.8 Short Term Management Plan & AOD treatment plan
2. Inpatient Unit - inpatient Treatment Plan
3. Residential Rehabilitation Unit - Recovery Action Plan
4. Fagerstrom Test for Nicotine Dependence

Planning a nicotine withdrawal regimen is dependent on the consumer’s intention to quit and/or detention status under the Mental Health Act (1986).
1. If the consumer has no intention to quit smoking and often leaves the unit, no intervention is required, however advise consumer that “quit” options are available.
2. If the consumer has intention to quit smoking or is unable to leave the unit, intervention is required
Precautions

Interaction effects with medications
Nicotine and other tobacco components may interact with and affect the action and metabolism of some medication and drugs such as clozapine and olanzapine. Changes in metabolism may occur upon cessation of smoking or Nicotine Replacement Therapy (NRT) and consideration should be given to the revision of dosages of other medications.

Metabolic effects
Clients withdrawing from nicotine should be informed of the body’s ability to more readily metabolise and absorb caffeine (i.e. coffee, chocolate, tea and soft drinks). An increase in caffeine levels may lead to increased restlessness and sleep disturbances.

Depression and Anxiety
Clinicians should monitor consumers for signs of depression and anxiety.

Withdrawal features
Nicotine withdrawal symptoms generally present within hours of the last cigarette and peak in the first 24 - 72 hours. Most symptoms will then decline and resolve within two to four weeks, although some symptoms may fluctuate longer.

Nicotine withdrawal symptoms include:
- Dysphoric or depressed mood
- Insomnia
- Irritability, frustration or anger
- Anxiety
- Difficulty concentrating
- Restlessness
- Decreased heart rate
- Increased appetite or weight gain

(Source: DSM-IV-TR (2000))
6.3 Management

Reference Forms:
1. Progress Notes
2. Medication Charts

Supportive Care
Clinical staff to:
1. Provide supportive counselling including advising coping strategies for cravings, maintaining motivation, sleep hygiene, relaxation techniques and patience.
2. Provide written information about withdrawal from nicotine, e.g. Quit Victoria’s ‘Stopping smoking information sheets’
3. Inform consumers of telephone counselling available from Quitline (13 7848)

Nutrition & Fluids
Encourage the consumer to:
1. Drink plenty of fluids (e.g. 2-3 litres of water or fruit juice daily)
2. Avoid caffeine and/or alcohol.
3. Eat light and healthy meals (small meals several times a day are better than one large meal)

Medication
1. First-line pharmacotherapy for nicotine withdrawal is nicotine replacement therapy (NRT).
2. Varenicline and bupropion sustained-release are other first-line options that can be considered in community settings, however there are recent concerns regarding the neuropsychiatric side-effects of varenicline e.g. emergent suicidal ideation and behaviours, so this form of intervention requires close monitoring.
3. Nortriptyline can be used as a second-line option.

Nicotine Replacement Therapy (NRT)
1. There are four main types of NRT - patches, gum, inhalers, & lozenges.
2. Clinical staff need to consider consumer’s possible high nicotine tolerance. Combinations of patch and other NRT or use of two patches may be used.

Refer to summary Table 10.
Table 10: Nicotine replacement therapies: dose, duration, side-effects and contraindications

<table>
<thead>
<tr>
<th>Type</th>
<th>Dose &amp; duration</th>
<th>Side effects</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patches</td>
<td>Low dependence 0-9 cigarettes per day</td>
<td>Nicobate® 14mg (if requirement not met increase patch to 21mg/24 hrs OR Nicorette® 10mg)</td>
<td>Transient skin irritation, itching, dreams, sleep disturbance, indigestion, diarrhoea</td>
</tr>
<tr>
<td></td>
<td>Moderate to high dependence 10-20 cigarettes per day</td>
<td>Nicobate® 21mg, Nicobate® 15mg</td>
<td></td>
</tr>
<tr>
<td>Gum</td>
<td>None</td>
<td>2mg, 8-12 per day</td>
<td>Jaw discomfort, nausea, indigestion, hiccups, excess saliva, sore throat</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4mg, 8-12 per day</td>
<td></td>
</tr>
<tr>
<td>Inhaler</td>
<td>None</td>
<td>Nicorette® 6-12 cartridges per day</td>
<td>Not recommended</td>
</tr>
</tbody>
</table>
6.4 Post- Withdrawal Care

Reference Forms:

1. Progress Notes
2. Inpatient Unit - Discharge Summaries
3. Residential Rehabilitation Units - Recovery Action Plans

Clinical staff must be aware that inpatient withdrawal services can be a life-saving intervention for some clients. However, on its own, withdrawal treatment is not associated with long-term benefits. Ongoing participation in treatment is required to achieve long-term changes.

Clinical staff must encourage all consumers attempting withdrawal to pursue ongoing drug treatment. In consultation with the consumer, plan for post withdrawal care options.

Consult with Quitline (13 78 48) regarding post-withdrawal treatment options and provide consumers with Quitline contact details and information.
7 Clinical Support And Information Services

Drug and Alcohol Clinical Advisory Service (DACAS) - 1800 812 804
www.dacas.org.au
DACAS is a 24 hour, 7 day telephone service available to health professionals in Victoria, Tasmania and the Northern Territory. DACAS can provide assistance with:

- Assessment
- Medical management of withdrawal syndromes
- Substitution pharmacotherapy and other prescribing issues
- Medical and nursing management of intoxication and toxicity
- Management of medical and psychiatric complications associated with drug and alcohol use
- Drug interactions
- Pain management

Drug and Poisons Regulation Group (DPRG) - 1300 364 545
DPRG is a branch of the Department of Health that informs health professionals of their legal requirements under the Drugs, Poisons and Controlled Substances Act 1981 and the Drugs, Poisons and Controlled Substances Regulations 2006 in relation to prescription medication and includes information regarding:

- The prescription of schedule 2,3,4 & 8 poisons
- Computer-generated prescriptions
- Permits to prescribe schedule 8 poisons
- Drug seeking behaviour
- Notification requirement of drug-dependence

Medicare Australia’s Prescription Shopping information Service - 1800 631 181
Doctors can access this 24 hour 7 days a week service to identify patients who they suspect are getting PBS medicines in excess of medical need. Medicare Australia can also contact a prescriber if their patient is identified under the Prescription Shopping Program.
Substance Use and Mental Illness Treatment Team (SUMITT) - 8387 2202

Dual Diagnosis - Australia and New Zealand

SUMITT is an initiative of the Department of Health and is auspiced by NorthWestern Mental Health (NWMH). The aim of SUMITT is to provide high quality services to individuals who have co-occurring mental health and substance-related disorders and build the capacity of the mental health, PDRSS and alcohol and other drug services to provide evidence based accessible and integrated treatment and care to these consumers and their carers.

SUMITT consists of a multidisciplinary staff group including a consultant psychiatrist, psychiatry registrar and senior clinicians. SUMITT senior clinicians provide primary, secondary and tertiary consultation and education and training on dual diagnosis related issues.

Consumer Support Services

DirectLine - 1800 888 236

DirectLine provides 24-hour, 7-day telephone counselling, information and referral service for people using drugs, family members, relatives and friends of someone using drugs, health and welfare professionals.

The service includes:

- Immediate counselling and support, including crisis intervention
- Support in dealing with the impact of drug use on the family
- Assistance in developing strategies to deal with alcohol or drug problems
- Information about how to reduce the harm associated with drug use
- Information and referral to treatment and support services across Victoria
- Links to further information and education resources

Specialist Services

Cannabis Information and Helpline - 1800 30 40 50
www.ncpic.org.au/ncpic/helpline

A confidential information and support line for cannabis users and friends and family who are concerned about cannabis use by those close to them. The service includes: the provision of counselling, information and referral details. Hours of operation: 11am - 8pm Monday to Friday (including public holidays).

DASWest Alcohol and Drug Services - (03) 8345 6682
http://www.wh.org.au/Corporate_Information/Our_Services/DasWest_Drug_and_Alcohol_Services/index.aspx

Based in the western suburbs of Melbourne; Footscray and Sunshine, DASWest provides a full range of AOD residential and treatment services including outreach based on a harm minimisation philosophy.
Methamphetamine Intervention Program


The methamphetamine Intervention Program available through Turning point provides support, information and treatment for those who use stimulant type drugs such as speed, ice and coke.

The service provides support-counselling sessions based on a Cognitive Behavioural Therapy (CBT) model to address stimulant use.

Additional services include:

- Information about amphetamines and other drugs
- Education and harm reduction advice
- Assessment
- Withdrawal support
- Individual counselling
- Medical treatment for dependence
- Mental health intervention
- Group support
- Referral to other health services

Moreland Hall

http://www.morelandhall.org

Moreland Hall is an Alcohol and Other Drugs (AOD) Treatment and Education agency predominantly servicing the North Western region of Melbourne. Moreland Hall is a Registered Training Organisation (RTO) providing a range of client education programs.

Treatment services include:

- Triage assessment and intake
- Counselling
- Family services including youth services, family counsellor and a family and friends support group
- Group program for clients and families including a playgroup, action based 6 week recovery program (ARC), keeping going a support group that encourages and maintains positive changes in your life
- Catalyst - Alcohol rehabilitation program - a 6 week evidence-based structured non-residential post withdrawal treatment program
Quitline - 137 848
A national telephone support service for smokers who want to quit.
Trained advisors provide advice, freely available resources and support and are available between 8am - 8pm Mon - Fri.

Reconnexion - 1300 273 266
www.reconnexion.org.au
A state-wide not-for-profit counselling service that specialises in benzodiazepine dependency, anxiety, depression and related problems.
Additional services include:
• Telephone support and information service (Mon - Fri : 9am - 5pm)
• Secondary consultation
• Group programs: sleep, social phobia, mindfulness CBT, meditation, art therapy
• An annual Anxiety and Depression Conference
• Tailored education programs for health professionals.

Websites
Dual Diagnosis Australia and New Zealand
http://www.dualdiagnosis.org.au/home

Dual Diagnosis Support Victoria
http://dualdiagnosis.ning.com
Both websites provide helpful information, resources and/or a forum for discussion to support clinicians in their work with clients with mental health and alcohol and/or drug related problems.
8 References


DACAS Fax sheets (2010). Turning Point Alcohol & Drug Centre (Vic). Fitzroy: Melbourne


Appendix 1: Melbourne Health Alcohol Withdrawal Scale (AWS)
Appendix 2: Fagerstrom Test
### ALCOHOL WITHDRAWAL SCALE

**Adapted from scale used by St Vincent’s Hospital, Melbourne**

Use this scale in conjunction with the Alcohol Withdrawal Chart over page

**WARD:** __________  **DATE:** __________  **DAY OF WITHDRAWAL:** __________

<table>
<thead>
<tr>
<th>Item 1: Perspiration</th>
<th>Item 6: Hallucination</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 No abnormal sweating</td>
<td>0 No evidence of hallucinations</td>
</tr>
<tr>
<td>1 Moist skin</td>
<td>1 Distortion of real objects – aware these are not real if pointed out</td>
</tr>
<tr>
<td>2 Localised beads of sweat, eg on face, chest</td>
<td>2 Appearance of new objects/perceptions – aware these are not real if pointed out</td>
</tr>
<tr>
<td>3 Whole body wet from perspiration</td>
<td>3 Believes hallucinations are real, still oriented in place and person</td>
</tr>
<tr>
<td>4 Profuse maximal sweating: clothes, linen etc. are wet</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Item 2: Tremor</th>
<th>Item 7: Orientation</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 No tremor</td>
<td>0 Patient is fully oriented in time, place and person</td>
</tr>
<tr>
<td>1 Slight intention tremor</td>
<td>1 Patient is oriented in person but is not sure what time it is or where he/she is</td>
</tr>
<tr>
<td>2 Constant slight tremor of upper extremities</td>
<td>2 Oriented in person but disoriented in time and place</td>
</tr>
<tr>
<td>3 Constant marked tremor of extremities</td>
<td>3 Doubtful personal orientation, disoriented in time and place; there may be short periods of lucidity</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Item 3: Anxiety</th>
<th>Item 8: Headache</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 No apprehension or anxiety</td>
<td>0 Not present</td>
</tr>
<tr>
<td>1 Slight apprehension</td>
<td>1 Mild</td>
</tr>
<tr>
<td>2 Apprehension or understandable fear, eg of withdrawal symptoms</td>
<td>2 Moderate</td>
</tr>
<tr>
<td>3 Anxiety occasionally accentuated to a state of panic</td>
<td>3 Severe</td>
</tr>
<tr>
<td>4 Constant panic-like anxiety</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Item 4: Agitation</th>
<th>Item 9: Facial Flushing</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 Rests normally during day, no signs of agitation</td>
<td>0 None</td>
</tr>
<tr>
<td>1 Slight restlessness, cannot sit or lie still, awake when others are asleep</td>
<td>1 Mild to Moderate</td>
</tr>
<tr>
<td>2 Moves constantly, looks tense, wants to get out of bed but obeys request to stay in bed</td>
<td>2 Severe</td>
</tr>
<tr>
<td>3 Constant restlessness, gets out of bed for no obvious reason, returns to bed if taken</td>
<td></td>
</tr>
<tr>
<td>4 Maximally restless, aggressive, ignores requests to stay in bed</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Item 5: Nausea and Vomiting</th>
<th>Item 10: Seizures</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 No nausea and no vomiting</td>
<td>0 None</td>
</tr>
<tr>
<td>1 Mild nausea and no vomiting</td>
<td>1 Generalized seizures</td>
</tr>
<tr>
<td>2 Intermittent nausea and dry heaves</td>
<td></td>
</tr>
<tr>
<td>3 Constant nausea, frequent dry heaves and vomiting</td>
<td></td>
</tr>
</tbody>
</table>
**ALCOHOL WITHDRAWAL CHART**

Use this chart in conjunction with the Alcohol Withdrawal Scale over page.

<table>
<thead>
<tr>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>5</td>
</tr>
<tr>
<td>6</td>
</tr>
<tr>
<td>7</td>
</tr>
<tr>
<td>8</td>
</tr>
<tr>
<td>9</td>
</tr>
<tr>
<td>10</td>
</tr>
</tbody>
</table>

**TOTAL SCORE**

<table>
<thead>
<tr>
<th>Item</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vital Signs</td>
</tr>
<tr>
<td>Temperature</td>
</tr>
<tr>
<td>Pulse</td>
</tr>
<tr>
<td>Respiration</td>
</tr>
<tr>
<td>BP</td>
</tr>
<tr>
<td>Medication</td>
</tr>
</tbody>
</table>

**Treatment guide based on Score**

- **Score < 10**: Supportive nursing care (See Intranet under Services)
- **Score > 10**: Use of diazepam 20 mg every two hours until withdrawal scale is <10 and anxiety/agitation is relieved

Note: For the withdrawal scale to be an accurate indication of the severity of the withdrawal, other significant medical (e.g., myocardial infarction, pneumonia) or psychological (anxiety, mania) conditions need to be excluded. Ensure that there are no other cases for withdrawal symptoms before relying on the withdrawal scale.

Fairly high doses of diazepam may be required if the patient has developed tolerance to benzodiazepines. This will have occurred if the patient has been on benzodiazepines for a considerable period of time before this admission. The titration rate may need to be changed to hourly under these circumstances. Dosed over 80 mg a day as an outpatient, or 120 mg per day as an inpatient, should be discussed with the MH Drug and Alcohol Liaison Service (Pager 9328) or the DACAS Service (1800 888 236).

The doses of diazepam should be given orally or carefully intravenously. Diazepam is very sclerosant and can cause significant damage if extravasated. There is no place for intramuscular diazepam, as the drug is only very slowly absorbed from the tissues.

Ensure that the patient has adequate nutrition, in particular give the multi-B vitamins and in particular thiamine, at least 100 mg orally twice a day. When in doubt about oral absorption, the intramuscular route can be used.

If the patient is becoming confused and delirious, major tranquilizers may be needed. These should only be given once the patient has been adequately loaded with diazepam because major tranquilizers can decrease the seizure threshold, increasing the chances of fitting. Once adequately loaded with diazepam, haloperidol 5 mg IM/IV at half hourly intervals to a maximum of 15mg. Alternatively olanzapine wafers or IM, 5mg half hourly or a maximum of 15mg.

Alcohol withdrawal can start from 6-48hrs after the ceasing of alcohol. It peaks in severity on days two and three and is usually over between 5-7 days after cessation.
Fagerstrom Test for Nicotine Dependence *

Is smoking “just a habit” or are you addicted? Take this test and find out your level of dependence on nicotine.

1. How soon after you wake up do you smoke your first cigarette?
   - After 60 minutes (0)
   - 31-60 minutes (1)
   - 6-30 minutes (2)
   - Within 5 minutes (3)

2. Do you find it difficult to refrain from smoking in places where it is forbidden?
   - No (0)
   - Yes (1)

3. Which cigarette would you hate most to give up?
   - The first in the morning (1)
   - Any other (0)

4. How many cigarettes per day do you smoke?
   - 10 or less (0)
   - 11-20 (1)
   - 21-30 (2)
   - 31 or more (3)

5. Do you smoke more frequently during the first hours after awakening than during the rest of the day?
   - No (0)
   - Yes (1)

6. Do you smoke even if you are so ill that you are in bed most of the day?
   - No (0)
   - Yes (1)


Click for score:

Your score was: . Your level of dependence on nicotine is: .

0-2 Very low dependence 6-7 High dependence
3-4 Low dependence 8-10 Very high dependence
5 Medium dependence

Scores under 5: Your level of nicotine dependence is still low. You should act now before your level of dependence increases.

Score of 5: Your level of nicotine dependence is moderate. If you don’t quit soon, your level of dependence on nicotine will increase until you may be seriously addicted. Act now to end your dependence on nicotine.

Score over 7: Your level of dependence is high. You aren’t in control of your smoking - it is in control of you! When you make the decision to quit, you may want to talk with your doctor about nicotine replacement therapy or other medications to help you break your addiction.